Advertisement

Author: Mariah Taylor

The growing popularity of Ozempic and other GLP-1s in recent years is garnering greater attention from oncologists interested in how these drugs could affect cancer care and cancer rates.

Advertisement

Cancer deaths are down over the past three decades, but cancerphobia is as strong as ever, Washington Post columnist Steven Petrow reported July 5.

There are more than 18 million cancer survivors living in the U.S., but few primary care providers know how to care for this patient group. To close the gap, Houston-based the University of Texas MD Anderson Cancer Center is launching…

Advertisement